Electronic Clinical Decision Support for Middle Eastern Hospitals

First DataBankHospitals in the Middle East are set to benefit from sophisticated electronic clinical decision support following the commercial agreement between First DataBank International (FDB International) and GE Healthcare (GE). This agreement builds on the relationship which First DataBank has with GE Healthcare's Information Technology business in the US.

GE's Centricity® Enterprise, will provide Middle Eastern customers with electronic dispensing and prescribing functionality, with clinical decision support enabled by the integration of FDB International's drug knowledge base. Healthcare providers can use Centricity® Enterprise to help verify the medication about to be prescribed or dispensed to a patient against the patient's profile. On-screen alerts help a provider to determine if there may be a potential drug interaction, duplicate therapy, sensitivity, contraindication or precaution.

Centricity® Enterprise is an integrated clinical, financial and administrative system that helps caregivers provide enhanced patient care through computerized physician order entry (CPOE), clinical decision support and expert rules, while documenting all aspects of patient care. The system integrates core clinical processes for orders, results, pharmacy and care documentation, in concert with administrative/financial processes for scheduling, registration/admitting, charging and billing.

"This agreement gives us access to invaluable information which will immediately benefit our product," said Juergen Reyinger, EMEA vice president and general manager of GE Healthcare IT. "We look forward to working with First DataBank International in growing our solution and benefiting from their strengths, just as they will surely benefit from ours."

David Flavell, President, FDB International adds: "The Middle East is a key region in our international expansion plans as its healthcare systems are developing so rapidly. Our agreement with GE is significant as it will bring more advanced clinical decision support to hospitals in the region, helping providers to enhance patient safety by helping them reduce the occurrence of medical errors."

First DataBank continues to expand its global presence with customers across the Middle East, Asia Pacific, Australasia, Africa and Europe as well as continuing to grow its long established North American and UK markets.

About First DataBank
First DataBank (FDB) is the world's leading provider of drug knowledge bases and active clinical decision support. With over 30 years' experience of maintaining, developing and integrating drug knowledge bases across the entire healthcare spectrum, FDB has unrivalled expertise and knowledge in this specialist field. NHS Connecting for Health has chosen FDB to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. Through the effective integration of our products into clinical systems, we enable safer prescribing, dispensing and administration.

For further information visit www.firstdatabank.co.uk.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease. For further information visit www.gehealthcare.com.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...